Compare ACADIA Pharmaceuticals Inc. (ACAD) vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $40.26. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | QDTY | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $28.06 | $46.71 |
52-Week Low | $20.06 | $36.57 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
QDTY trades at $41.16, up 1.66% today, but technical indicators signal a bearish trend with moving averages and overall signals pointing lower. The stock exhibits weekly dividend distributions, with recent payouts ranging from $0.22 to $0.32. Support and resistance levels are clustered near the current price, indicating potential volatility. Recent news focuses heavily on dividend announcements from YieldMax ETFs, with minimal coverage of broader business performance or financial results.
The outlook remains cautious due to weak technical momentum and lack of fundamental data. Investment opportunity hinges on dividend yield sustainability, but risks include absence of earnings visibility and bearish technical pressure. Key catalysts for reversal would require positive earnings surprises or upward analyst revisions, which are currently unavailable.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →
